Gilead Begins to Fill the Hole in its Pipeline

By Business Review Editor

Pharma Deals Review: Vol 2005 Issue 59 (Table of Contents)

Published: 5 May-2005

DOI: 10.3833/pdr.v2005.i59.684     ISSN: 1756-7874

Section: General

Abstract

Gilead Sciences entered into licensing agreement with Japan Tobacco (JT) to develop and commercialize Japan Tobacco’s HIV integrase inhibitor (JTK-303) in all countries of the world, excluding Japan...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details